Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 8 | 2023 | 410 | 1.860 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2024 | 71 | 1.800 |
Why?
|
| Electrocardiography | 12 | 2022 | 623 | 1.490 |
Why?
|
| Heart Failure | 11 | 2024 | 728 | 1.150 |
Why?
|
| Syncope | 2 | 2022 | 25 | 0.980 |
Why?
|
| Risk Assessment | 13 | 2024 | 1425 | 0.870 |
Why?
|
| Defibrillators, Implantable | 5 | 2021 | 44 | 0.850 |
Why?
|
| Coronary Disease | 2 | 2024 | 226 | 0.820 |
Why?
|
| Cryosurgery | 1 | 2023 | 25 | 0.770 |
Why?
|
| Risk Factors | 18 | 2024 | 3934 | 0.740 |
Why?
|
| C-Reactive Protein | 3 | 2014 | 227 | 0.720 |
Why?
|
| Stroke | 6 | 2022 | 691 | 0.700 |
Why?
|
| Humans | 47 | 2024 | 32274 | 0.690 |
Why?
|
| Atherosclerosis | 2 | 2024 | 820 | 0.620 |
Why?
|
| Catheter Ablation | 1 | 2021 | 113 | 0.620 |
Why?
|
| Middle Aged | 26 | 2024 | 11848 | 0.600 |
Why?
|
| Heart | 2 | 2020 | 177 | 0.580 |
Why?
|
| Stroke Volume | 7 | 2024 | 417 | 0.580 |
Why?
|
| Male | 32 | 2024 | 19437 | 0.540 |
Why?
|
| Exercise Therapy | 2 | 2012 | 250 | 0.530 |
Why?
|
| Aged | 24 | 2024 | 10260 | 0.520 |
Why?
|
| Female | 31 | 2024 | 19942 | 0.480 |
Why?
|
| Hypertension | 4 | 2017 | 979 | 0.480 |
Why?
|
| Prospective Studies | 12 | 2022 | 2316 | 0.420 |
Why?
|
| Coronary Artery Disease | 2 | 2021 | 427 | 0.410 |
Why?
|
| Hospitalization | 4 | 2024 | 475 | 0.400 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 773 | 0.390 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 293 | 0.390 |
Why?
|
| Kidney | 1 | 2016 | 521 | 0.370 |
Why?
|
| Inflammation | 2 | 2021 | 506 | 0.360 |
Why?
|
| Heart Ventricles | 4 | 2021 | 146 | 0.360 |
Why?
|
| Earthquakes | 1 | 2011 | 2 | 0.350 |
Why?
|
| Echocardiography | 7 | 2018 | 190 | 0.350 |
Why?
|
| Disasters | 1 | 2011 | 12 | 0.350 |
Why?
|
| International Cooperation | 1 | 2011 | 31 | 0.350 |
Why?
|
| Ventricular Function, Left | 6 | 2022 | 264 | 0.350 |
Why?
|
| Interleukin-6 | 2 | 2009 | 224 | 0.330 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2017 | 168 | 0.330 |
Why?
|
| Incidence | 7 | 2024 | 1241 | 0.320 |
Why?
|
| United States | 9 | 2022 | 4072 | 0.310 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2009 | 7 | 0.310 |
Why?
|
| Life Style | 1 | 2012 | 393 | 0.300 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 26 | 0.300 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2009 | 10 | 0.300 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 183 | 0.290 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 98 | 0.290 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 96 | 0.290 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 84 | 0.280 |
Why?
|
| Cardiomyopathies | 1 | 2009 | 67 | 0.280 |
Why?
|
| Heart Rate | 3 | 2020 | 362 | 0.280 |
Why?
|
| Vascular Diseases | 1 | 2008 | 66 | 0.270 |
Why?
|
| Japan | 3 | 2012 | 19 | 0.270 |
Why?
|
| Aortic Valve Stenosis | 3 | 2017 | 40 | 0.260 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 155 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2023 | 3416 | 0.250 |
Why?
|
| Candidiasis | 1 | 2006 | 6 | 0.250 |
Why?
|
| African Americans | 4 | 2020 | 1335 | 0.250 |
Why?
|
| Ventricular Fibrillation | 1 | 2006 | 6 | 0.250 |
Why?
|
| Malaria | 1 | 2006 | 13 | 0.250 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2020 | 28 | 0.240 |
Why?
|
| Abscess | 1 | 2006 | 28 | 0.240 |
Why?
|
| Exercise | 3 | 2021 | 603 | 0.240 |
Why?
|
| Anticoagulants | 3 | 2022 | 122 | 0.230 |
Why?
|
| Prognosis | 7 | 2022 | 1534 | 0.230 |
Why?
|
| Mississippi | 6 | 2024 | 38 | 0.230 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 363 | 0.220 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2021 | 17 | 0.210 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2017 | 122 | 0.210 |
Why?
|
| Ankle Brachial Index | 1 | 2024 | 38 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 2240 | 0.200 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 1158 | 0.200 |
Why?
|
| Myocardium | 3 | 2018 | 184 | 0.190 |
Why?
|
| Smoking Cessation | 1 | 2024 | 211 | 0.180 |
Why?
|
| Desmoglein 2 | 1 | 2021 | 1 | 0.180 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2021 | 2 | 0.180 |
Why?
|
| Bisoprolol | 1 | 2021 | 2 | 0.180 |
Why?
|
| Flecainide | 1 | 2021 | 2 | 0.180 |
Why?
|
| Ventricular Remodeling | 2 | 2022 | 63 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2021 | 26 | 0.170 |
Why?
|
| Tachycardia | 2 | 2012 | 6 | 0.170 |
Why?
|
| Adult | 10 | 2024 | 9256 | 0.170 |
Why?
|
| HIV Infections | 1 | 2006 | 450 | 0.160 |
Why?
|
| Hemorrhage | 3 | 2022 | 95 | 0.160 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 59 | 0.160 |
Why?
|
| Prevalence | 3 | 2020 | 955 | 0.160 |
Why?
|
| Ventricular Premature Complexes | 1 | 2020 | 20 | 0.160 |
Why?
|
| Time Factors | 5 | 2024 | 2204 | 0.160 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 28 | 0.160 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 50 | 0.160 |
Why?
|
| Atrial Premature Complexes | 1 | 2020 | 22 | 0.160 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 126 | 0.150 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2019 | 17 | 0.150 |
Why?
|
| Heart Conduction System | 1 | 2020 | 76 | 0.150 |
Why?
|
| European Continental Ancestry Group | 2 | 2020 | 1076 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 3898 | 0.150 |
Why?
|
| Body Size | 1 | 2019 | 35 | 0.150 |
Why?
|
| Neck | 1 | 2019 | 32 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2021 | 1840 | 0.140 |
Why?
|
| Leptin | 1 | 2018 | 61 | 0.140 |
Why?
|
| Osteoprotegerin | 1 | 2017 | 2 | 0.140 |
Why?
|
| Atrioventricular Block | 1 | 2017 | 4 | 0.130 |
Why?
|
| Bradycardia | 1 | 2017 | 17 | 0.130 |
Why?
|
| Heart Block | 1 | 2017 | 10 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 19 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 39 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2020 | 458 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 68 | 0.130 |
Why?
|
| Rest | 1 | 2017 | 48 | 0.130 |
Why?
|
| Aorta | 1 | 2017 | 125 | 0.120 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2016 | 4 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 101 | 0.120 |
Why?
|
| Creatinine | 1 | 2016 | 191 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2016 | 55 | 0.120 |
Why?
|
| Cause of Death | 2 | 2017 | 236 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 302 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 883 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 757 | 0.110 |
Why?
|
| Survival Rate | 2 | 2017 | 893 | 0.100 |
Why?
|
| Blood Pressure | 3 | 2020 | 861 | 0.100 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2013 | 13 | 0.100 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2013 | 17 | 0.100 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2012 | 2 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 502 | 0.090 |
Why?
|
| Dehydration | 1 | 2012 | 8 | 0.090 |
Why?
|
| Anecdotes as Topic | 1 | 2011 | 2 | 0.090 |
Why?
|
| Telemetry | 1 | 2011 | 24 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 541 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2017 | 3624 | 0.080 |
Why?
|
| Recurrence | 1 | 2012 | 285 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2011 | 273 | 0.080 |
Why?
|
| Heart Atria | 1 | 2011 | 81 | 0.080 |
Why?
|
| Sex Factors | 3 | 2019 | 655 | 0.080 |
Why?
|
| Patient Participation | 2 | 2022 | 90 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1111 | 0.080 |
Why?
|
| Biological Markers | 1 | 2009 | 2 | 0.080 |
Why?
|
| Disease Progression | 1 | 2011 | 591 | 0.070 |
Why?
|
| Fibrinogen | 1 | 2009 | 65 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2009 | 60 | 0.070 |
Why?
|
| Animals, Genetically Modified | 1 | 2009 | 68 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2009 | 100 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2009 | 159 | 0.070 |
Why?
|
| Rabbits | 1 | 2009 | 219 | 0.070 |
Why?
|
| Exercise Test | 1 | 2009 | 217 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 120 | 0.070 |
Why?
|
| Quality of Life | 1 | 2013 | 964 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2008 | 72 | 0.070 |
Why?
|
| Gene Expression | 1 | 2009 | 345 | 0.070 |
Why?
|
| Genotype | 1 | 2009 | 702 | 0.070 |
Why?
|
| Actomyosin | 1 | 2007 | 3 | 0.070 |
Why?
|
| New York | 1 | 2006 | 20 | 0.060 |
Why?
|
| Remission Induction | 1 | 2006 | 92 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 66 | 0.060 |
Why?
|
| Age Factors | 2 | 2020 | 1179 | 0.060 |
Why?
|
| Bundle-Branch Block | 1 | 2006 | 22 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 59 | 0.060 |
Why?
|
| Linear Models | 2 | 2017 | 425 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 651 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1083 | 0.060 |
Why?
|
| Ultrasonic Therapy | 1 | 2005 | 4 | 0.060 |
Why?
|
| Mitral Valve | 1 | 2005 | 33 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2005 | 58 | 0.050 |
Why?
|
| Warfarin | 1 | 2022 | 32 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2021 | 18 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2021 | 47 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 186 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2012 | 413 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 272 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 99 | 0.040 |
Why?
|
| Animals | 2 | 2009 | 8199 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2019 | 25 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 128 | 0.040 |
Why?
|
| Triglycerides | 1 | 2020 | 235 | 0.040 |
Why?
|
| Action Potentials | 1 | 2020 | 212 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2020 | 228 | 0.040 |
Why?
|
| Insulin | 1 | 2020 | 359 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2020 | 484 | 0.030 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2017 | 1 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 221 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2017 | 14 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 98 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 20 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 42 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2017 | 66 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 50 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 158 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 34 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 72 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 98 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 287 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 324 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 78 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2017 | 171 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2017 | 128 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 565 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 248 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2017 | 135 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 355 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 863 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 854 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 853 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1479 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 245 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2013 | 164 | 0.020 |
Why?
|
| Cardiography, Impedance | 1 | 2012 | 5 | 0.020 |
Why?
|
| Anxiety | 1 | 2013 | 190 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1010 | 0.020 |
Why?
|
| Sarcomeres | 1 | 2007 | 5 | 0.020 |
Why?
|
| Myosins | 1 | 2007 | 12 | 0.020 |
Why?
|
| Elasticity | 1 | 2007 | 41 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 155 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2007 | 54 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 250 | 0.020 |
Why?
|
| Protein Binding | 1 | 2007 | 244 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2007 | 251 | 0.010 |
Why?
|
| Transducers | 1 | 2005 | 14 | 0.010 |
Why?
|
| Mitral Valve Stenosis | 1 | 2005 | 9 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 408 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 116 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 520 | 0.010 |
Why?
|